Hoffmann-la Roche
Clinical trials sponsored by Hoffmann-la Roche, explained in plain language.
-
New MS drug trial for kids: could ocrelizumab help?
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New targeted pill aims to keep KRAS lung cancer from returning after surgery
Disease control Not yet recruitingThis study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New arthritis drug afimkibart tested for Long-Term safety
Disease control Not yet recruitingThis study looks at the long-term safety and effectiveness of the drug afimkibart for people with moderate to severe rheumatoid arthritis who have not responded well to other treatments. It includes 120 adults who have already taken afimkibart in a previous study. The goal is to …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New study tracks Risdiplam's Real-World impact on spinal muscle atrophy
Disease control Not yet recruitingThis study follows about 30 people with Type I or Type II spinal muscle atrophy who are taking risdiplam. Researchers will watch how their muscle strength and movement change over 24 months, using standard tests. The goal is to see how well the drug works in everyday life, not in…
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug cocktail aims to supercharge weight loss in obesity trial
Disease control Not yet recruitingThis study tests whether combining two experimental drugs, petrelintide and enicepatide, helps adults with obesity or overweight lose more weight than taking either drug alone or a placebo. About 486 participants will receive different doses or a placebo for several months. The g…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New registry to track COPD Patients' daily struggles and treatments
Knowledge-focused Not yet recruitingThis study will follow 3,000 people with COPD who have frequent flare-ups to see how the disease changes over time and what treatments they receive. Researchers will collect information from medical records and surveys to understand treatment patterns, quality of life, and caregi…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:52 UTC
-
New drug enicepatide put to the test in first human safety study
Knowledge-focused Not yet recruitingThis early-stage study tests whether enicepatide is safe and how the body processes it in 36 healthy Chinese adults with a BMI of 23 or higher. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood. The goal…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:02 UTC